Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis

Davide Giuseppe Ribaldone, Rinaldo Pellicano, Marta Vernero, Gian Paolo Caviglia, Giorgio Maria Saracco, Mario Morino, Marco Astegiano

Research output: Contribution to journalReview article

Abstract

Background: Inflammatory bowel diseases patients eligible for biological therapy represent a group with considerable disease burden and biologics only achieve 40% clinical remission rates in responders after 1 year of therapy. Aims: To collect all the published data about patients treated with dual biological therapy with an Anti-TNF, vedolizumab or ustekinumab, for a period of at least 3 months and to pool the data about the effectiveness and safety. Methods: A MEDLINE, and Web of Science search of all studies published in English until 1 January 2019 was conducted. Results: We included 7 studies with a total of 18 patients. Fifteen patients were treated with a combination of an anti-TNF and vedolizumab, 3 patients were treated with vedolizumab and ustekinumab. Fifty-six percent of patients were affected by Crohn’s disease and 50% of patients were treated with an immunosuppressant drug or steroid too. A clinical improvement was obtained in 100% of patients, and an endoscopic improvement in 93% of patients. No serious adverse events were reported. Conclusions: The use of dual biological therapy is an attractive therapeutic option and may be an opportunity to better tailor and personalize the therapies for patients. Further studies, as randomized control trials, to provide comparative efficacy and safety endpoints of combination therapies, and to clarify potential advantages of combined biological therapies, are needed.

Original languageEnglish
Pages (from-to)407-413
Number of pages7
JournalScandinavian Journal of Gastroenterology
Volume54
Issue number4
DOIs
Publication statusPublished - Apr 3 2019
Externally publishedYes

Fingerprint

Biological Therapy
Inflammatory Bowel Diseases
vedolizumab
Ustekinumab
Safety
Therapeutics
Immunosuppressive Agents
Biological Products
MEDLINE
Crohn Disease
Steroids

Keywords

  • Anti-integrin
  • biologics
  • Crohn’s disease
  • inflammatory bowel disease
  • ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease : a systematic review with pool analysis. / Ribaldone, Davide Giuseppe; Pellicano, Rinaldo; Vernero, Marta; Caviglia, Gian Paolo; Saracco, Giorgio Maria; Morino, Mario; Astegiano, Marco.

In: Scandinavian Journal of Gastroenterology, Vol. 54, No. 4, 03.04.2019, p. 407-413.

Research output: Contribution to journalReview article

Ribaldone, Davide Giuseppe ; Pellicano, Rinaldo ; Vernero, Marta ; Caviglia, Gian Paolo ; Saracco, Giorgio Maria ; Morino, Mario ; Astegiano, Marco. / Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease : a systematic review with pool analysis. In: Scandinavian Journal of Gastroenterology. 2019 ; Vol. 54, No. 4. pp. 407-413.
@article{dfdf9ebfb7404678ad5aba735cc1b1dc,
title = "Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis",
abstract = "Background: Inflammatory bowel diseases patients eligible for biological therapy represent a group with considerable disease burden and biologics only achieve 40{\%} clinical remission rates in responders after 1 year of therapy. Aims: To collect all the published data about patients treated with dual biological therapy with an Anti-TNF, vedolizumab or ustekinumab, for a period of at least 3 months and to pool the data about the effectiveness and safety. Methods: A MEDLINE, and Web of Science search of all studies published in English until 1 January 2019 was conducted. Results: We included 7 studies with a total of 18 patients. Fifteen patients were treated with a combination of an anti-TNF and vedolizumab, 3 patients were treated with vedolizumab and ustekinumab. Fifty-six percent of patients were affected by Crohn’s disease and 50{\%} of patients were treated with an immunosuppressant drug or steroid too. A clinical improvement was obtained in 100{\%} of patients, and an endoscopic improvement in 93{\%} of patients. No serious adverse events were reported. Conclusions: The use of dual biological therapy is an attractive therapeutic option and may be an opportunity to better tailor and personalize the therapies for patients. Further studies, as randomized control trials, to provide comparative efficacy and safety endpoints of combination therapies, and to clarify potential advantages of combined biological therapies, are needed.",
keywords = "Anti-integrin, biologics, Crohn’s disease, inflammatory bowel disease, ulcerative colitis",
author = "Ribaldone, {Davide Giuseppe} and Rinaldo Pellicano and Marta Vernero and Caviglia, {Gian Paolo} and Saracco, {Giorgio Maria} and Mario Morino and Marco Astegiano",
year = "2019",
month = "4",
day = "3",
doi = "10.1080/00365521.2019.1597159",
language = "English",
volume = "54",
pages = "407--413",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease

T2 - a systematic review with pool analysis

AU - Ribaldone, Davide Giuseppe

AU - Pellicano, Rinaldo

AU - Vernero, Marta

AU - Caviglia, Gian Paolo

AU - Saracco, Giorgio Maria

AU - Morino, Mario

AU - Astegiano, Marco

PY - 2019/4/3

Y1 - 2019/4/3

N2 - Background: Inflammatory bowel diseases patients eligible for biological therapy represent a group with considerable disease burden and biologics only achieve 40% clinical remission rates in responders after 1 year of therapy. Aims: To collect all the published data about patients treated with dual biological therapy with an Anti-TNF, vedolizumab or ustekinumab, for a period of at least 3 months and to pool the data about the effectiveness and safety. Methods: A MEDLINE, and Web of Science search of all studies published in English until 1 January 2019 was conducted. Results: We included 7 studies with a total of 18 patients. Fifteen patients were treated with a combination of an anti-TNF and vedolizumab, 3 patients were treated with vedolizumab and ustekinumab. Fifty-six percent of patients were affected by Crohn’s disease and 50% of patients were treated with an immunosuppressant drug or steroid too. A clinical improvement was obtained in 100% of patients, and an endoscopic improvement in 93% of patients. No serious adverse events were reported. Conclusions: The use of dual biological therapy is an attractive therapeutic option and may be an opportunity to better tailor and personalize the therapies for patients. Further studies, as randomized control trials, to provide comparative efficacy and safety endpoints of combination therapies, and to clarify potential advantages of combined biological therapies, are needed.

AB - Background: Inflammatory bowel diseases patients eligible for biological therapy represent a group with considerable disease burden and biologics only achieve 40% clinical remission rates in responders after 1 year of therapy. Aims: To collect all the published data about patients treated with dual biological therapy with an Anti-TNF, vedolizumab or ustekinumab, for a period of at least 3 months and to pool the data about the effectiveness and safety. Methods: A MEDLINE, and Web of Science search of all studies published in English until 1 January 2019 was conducted. Results: We included 7 studies with a total of 18 patients. Fifteen patients were treated with a combination of an anti-TNF and vedolizumab, 3 patients were treated with vedolizumab and ustekinumab. Fifty-six percent of patients were affected by Crohn’s disease and 50% of patients were treated with an immunosuppressant drug or steroid too. A clinical improvement was obtained in 100% of patients, and an endoscopic improvement in 93% of patients. No serious adverse events were reported. Conclusions: The use of dual biological therapy is an attractive therapeutic option and may be an opportunity to better tailor and personalize the therapies for patients. Further studies, as randomized control trials, to provide comparative efficacy and safety endpoints of combination therapies, and to clarify potential advantages of combined biological therapies, are needed.

KW - Anti-integrin

KW - biologics

KW - Crohn’s disease

KW - inflammatory bowel disease

KW - ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=85066872334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066872334&partnerID=8YFLogxK

U2 - 10.1080/00365521.2019.1597159

DO - 10.1080/00365521.2019.1597159

M3 - Review article

C2 - 30945576

AN - SCOPUS:85066872334

VL - 54

SP - 407

EP - 413

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 4

ER -